Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

Importance The immune response in children with SARS-CoV-2 infection is not well
understood. Objective To compare seroconversion in nonhospitalized children and adults …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is the target for
neutralizing antibodies elicited following both infection and vaccination. While extensive …

Most existing vaccines, delivered by intramuscular injection (IM), are typically associated
with stringent storage requirements under cold-chain distribution and professional …

Background The ability to quantify an immune response after vaccination against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential. This study assessed …

Background To investigate a vaccine technology with potential to protect against
coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory …

Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …